Living cardiovascular implants for a better quality
of life and lower total cost.
Xeltis AG was founded in 2006 as a spin-off from the University of Zurich, Switzerland. The company is developing novel therapeutic solutions for the treatment of cardiovascular and other diseases. Our goal is to improve the patient’s quality of life, while reducing the total cost of the therapy. 
We produce autologous growing, living, and self-healing cardio-vascular implants, using tissue-engineering technology. Our proprietary medical technologies have been developed over the past 15 years and allow us to offer new solutions, which show superior functionality and safety compared with all the contemporary technologies.